Wave Life Sciences' CEO Paul Bolno discusses Phase 1b/2a data from the company's allele-selective Huntington's program
Paul Bolno highlights biomarker and safety data in Huntington's, the potential regulatory path ahead, and what to watch throughout the rest of the year from Wave's DMD, AATD, and weight loss programs.